Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
|Articles|August 20, 2012
Considerations for the Development and Manufacturing of Biosimilars [Presentation]
Advertisement
This content is provided by Amgen.
Divided into 3 sections, this presentation provides insight into the complexities of developing and manufacturing biologics and discusses considerations for the development of biosimilars.
Please click the image below to view the presentation.
Advertisement
Related to this article
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5